Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1/2 2Phase 1 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Tumor-Agnostic 1Thoracic 1Other hematologic neoplasm 1Myeloid 1

Conditions

Recurrence 2Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma 1Hodgkin Disease 1

Interventions

Rituximab 169Cyclophosphamide 158fludarabine 76Lenalidomide 73Vincristine 70fludarabine phosphate 63Etoposide 59Doxorubicin 56Prednisone 54venetoclax 49Cytarabine 48Dexamethasone 43Filgrastim 39Peripheral Blood Stem Cell Transplantation 38Methotrexate 38Bendamustine Hydrochloride 38ibrutinib 37obinutuzumab 36Gemcitabine 31pembrolizumab 27Melphalan 27Bortezomib 27Alemtuzumab 25Radiotherapy 23Nivolumab 21Carboplatin 21Tacrolimus 20Granulocyte Colony-Stimulating Factor 20Busulfan 20Whole-Body Irradiation 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × mocetinostat × Lymphoid × Clear all
NCT02282358 2024-03-08

Study of Mocetinostat in Selected Patients With Mutations of Acetyltransferase Genes in Relapsed and Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma

Memorial Sloan Kettering Cancer Center

Phase 1/2 Terminated
7 enrolled 11 charts
Lymphoid

Lymphoma, Lymphoma, Follicular, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT02429375 2022-05-12

Mocetinostat (MGCD0103) Plus Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Hodgkin Lymphoma

Memorial Sloan Kettering Cancer Center

Phase 1/2 Completed
7 enrolled 10 charts
Lymphoid

Hodgkin Disease, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡